Brain Glucose Sensing and the Problem of Relative Hypoglycemia
Michael W Schwartz1, James S Krinsley2,3, Chelsea L Faber4
1Department of Medicine, University of Washington Medicine Diabetes Institute, Seattle, WA.
Diabetes Care
|January 26, 2023
Summary
Relative hypoglycemia, a diabetes complication, raises the glucose level needed to detect low blood sugar. This neuronal impairment may explain why intensive care glucose management differs for diabetic patients, impacting mortality risk.
Area of Science:
- Neuroscience
- Endocrinology
- Critical Care Medicine
Background:
- Relative hypoglycemia, an elevated glycemic threshold for hypoglycemia detection, is a complication in diabetes.
- Critically ill patients with diabetes and high HbA1c show lower mortality with higher ICU glucose, unlike non-diabetic patients.
- Cardiovascular stress from perceived hypoglycemia, even at normal glucose levels, may explain outcome differences.
Purpose of the Study:
- To investigate the brain's mechanisms for detecting hypoglycemia.
- To explore the development of relative hypoglycemia in diabetic patients.
- To examine the role of glucose-responsive neurons in hypoglycemia detection and relative hypoglycemia.
Main Methods:
- Exploration of glucose-responsive sensory neurons in peripheral vascular beds and circumventricular organs.
- Review of existing literature on hypoglycemia detection and diabetes-related complications.
Main Results:
- Diabetes impairs neuronal glucose-sensing mechanisms.
- This impairment raises the glycemic threshold for perceiving hypoglycemia.
- Relative hypoglycemia results from diabetes-associated impairment of neuronal glucose sensing.
Conclusions:
- Impaired neuronal glucose sensing in diabetes leads to relative hypoglycemia.
- This condition may increase mortality risk in critically ill diabetic patients undergoing standard glycemic management.
- Further research is needed to fully understand and manage relative hypoglycemia in critical care settings.
More Related Videos
Related Concept Videos
Hypoglycemia and Glucagon
310
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
310
Glucose Homeostasis: Regulation of Blood Glucose
1.9K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.9K
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Oral Hypoglycemic Agents: Glinides
204
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
204
Glucose Transporters
23.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.9K


